As a comparison, the survival data of all GC patients with HER2 amplification were also analyzed, and the results showed no significant difference between GC patients with or without HER2 amplification in terms of both DFS (P = 0.47) and OS (P = 0.39) (Fig. 1I-J). The gene discussed is ERBB2; the disease is gastric cancer.